Rare Opening In Tough Times: New Biotechs Rekindle CNS Development In China
But Regulatory Barriers Remain
A slew of high-level executives has established biotech startups in China with a single focus on CNS conditions. Emerging collaboration and funding flow highlights a heating up market, but insiders tell Scrip that choppy waters and an uncertain future may be looming.
